Anju Expands TA Scan Platform
Company to integrate European diversity data from the UK and demographics data from France and Spain.
Anju, a clinical technical solutions provider, announced the expansion of its TA Scan platform through the integration of European diversity data from the UK and demographics data from France and Spain. According to a company press release, TA Scan enables users to visualize essential data, such as ethnicity, socio-economic information, and site/investigator experience, all on a single map.
"TA Scan's expansion into European diversity data underscores our commitment to helping clinical research professionals meet their global study diversification goals," said Barbara Argibay, VP, development, data division, Anju. "Empowering users to optimize recruitment strategies, site/investigator/KOL selection, and diversity initiatives with ease, while maintaining the highest standards of data security and privacy."
Reference: Anju's TA Scan Expands Global Reach with European Diversity Data Integration. PR Newswire. October 17, 2023, Accessed October 20, 2023. https://www.prnewswire.com/news-releases/anjus-ta-scan-expands-global-reach-with-european-diversity-data-integration-301959425.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
